HIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials.

Authors :: Volk, J. E.
Hessol, N. A.
Gray, G. E.
Kublin, J. G.
Churchyard, G.
Mlisana, K.
Nchabeleng, M.
Buchbinder, S. P.
Bekker, L.
Source :: Retrovirology; 2012 Supplement, Vol. 9 Issue Suppl 2, p1-1, 1p
Publication Year :: 2012
Abstract: An abstract of the research paper "HIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials," by J.E. Volk and colleagues is presented.

Full Text Access

Tools